reason report
headwind continu usa volum ok reimburs
bottom line remain cautiou walgreen follow
result usa retail volum pretti good gross margin
deterior slow slightli remain concern industri
consolid preval narrow network caus sustain
reimburs pressur also concern us appar focu
continu build scale attempt mitig reimburs
pressur view pursuit scale signal
largest rival like continu compet volum like
lead continu margin pressur reimburs continu
pressur us pharmaci busi manag call improv
brand inflat tailwind encourag on-going
work drug price trend suggest headwind price also
like continu especi given focu gener deflat
also sound high us come declin adjust oper
incom enterpris usa retail
signific view continu navig variou headwind
sound like cost reduct program store
integr remain track howev expand store
labor invest us remain cautiou price
target stand
concern focu build addit scale
earn call co-chief oper offic alexand gourlay
explain one strategi grow volum make
busi bigger get scale scale typic afford
negoti power would presum better equip amid on-going
reimburs pressur alreadi domin market share
quarter pharmaci market share
bp y/i due on-going store optim still
command posit market despit command share
market continu face signific reimburs pressur
usa pharmaci gross margin contract bp y/i
manag call reimburs pressur mix shift
brand inflat growth specialti pharmaci worth bp
headwind primari driver view scale offset
reimburs pressur sure increment
increas scale provid relief
net debt total capit
price-to-earnings lt ep growth
ep
year price history/av daili volume mil
compani inform svb leerink llc research
ep exclud acquisition-rel cost acquisition-rel amort non-recur item includ lifo adjust revenu billion
pleas refer page import disclosur price chart analyst certif
guidanc re-affirmed chang long-term guidanc
provid last quarter manag re-affirmed guidanc
morn adj ep tweak sever assumpt adj ep
still expect roughli flat constant currenc basi
compar prior svb leerink/consensu estim
embed guidanc neg currenc impact slightli
larger includ last quarter guidanc addit
manag caution investor expect rang plu
minu guidanc includ share repurchas
adj ep growth effect tax rate vs
 embed prior guidanc manag expect store
labor invest signific portion
addit occur acceler
pace digit invest
manag program store optim
track combat variou headwind face busi
continu work transform manag program
accord manag compani remain track deliv
annual cost save previous disclos
reduc headcount uk headquart continu
pursu cost save initi follow review uk store
portfolio close store next month
two-third store reportedli within walk distanc
anoth boot store manag explain store
repres store base revenu manag
current review footprint us said
follow come month store optim
also sound like track close plan
store closur convert store compani
continu expect integr complet end
busi pressur year
encourag compani remain on-track cost save goal
still concern invest buy growth may
off-set cost reduct initi manag still call
annual save quarter increas
store labor invest signific portion
addit occur quarter
invest store labor detract bp adj
oper incom margin expans usa retail call
ceo stefano pessina said invest heavili updat
system infrastructur bid creat new incom stream
transform tradit area busi mr pessina continu
explain vision futur pharmaci wide rang
healthcar servic provid commun set presum
pharmaci caution singl one servic
defin frame futur view suggest may need
continu invest busi partnership develop mani
variou incom stream believ necessari futur
model updat follow quarter updat model
maintain price target adj ep remain
unchang adj ep increas slightli
price target adj ep
largest global pharmaci led retail pharmaceut wholesal
organ world walgreen us drugstor chain largest pharmaci chain
us store count industri size improv purchas power brand-nam
recognit improv store traffic overal volum health plan self-insur
employ seek reduc medic cost via restrict network believ walgreen in-stor
clinic may provid attract altern plan walgreen nation presenc
also attract mani plan view provid larg corpor broad access
view gener launch wave next sever year posit impact
bottom line walgreen balanc reward custom loyalti program help lower
print ad cost bring individu market benefit recent work increas wba
privat brand product share mix well new front-end merchandis strategi
posit impact same-stor sale profit addit walgreen recent deal allianc
boot abc/op offer promis long-term synergi global
growth back lost share esrx network disput
although grow accept narrow network remain risk walgreen provid
health plan wide array servic includ infus specialti dispens lab servic
hospit partnership primari care servic case walgreen also earli
mover advantag purchas jv boot deal walgreen
pbm may advantag case make retail chain payer agnost
mani strength believ retail channel face signific challeng
includ increasingli competit environ seek creat
restrict prefer narrow network deal effort captur store traffic volum
medacorp specialist check indic retail rate reduc
case keep pressur retail gross margin
furthermor on-going gener launch believ wave
larg behind us becom increasingli difficult show gross margin expans
retail also believ transact posit busi stock howev
deterior lose share even though deal approv investor
sentiment stock name appear low lastli threat amazon entri
pharmaci servic space continu weigh stock believ
retail exposur sinc own pbm given risk
concern rate share market perform
next month expect share trade ep
would put stock price multipl reflect on-going reimburs pressur
minim accret continu headwind intern busi
believ posit win share becom extens network
vast array clinic capabl believ new manag team take step
reduc overal cost increas sale higher margin front-stor product
posit retail rate remain signific pressur brand gener price also
headwind becom aggress overal respons market
also overhang unlik abat time soon given challeng concern
rate share market perform
competit high retail pharmaci industri highli competit contract
pbm manufactur also competit walgreen compet chain
independ drug store well mail order prescript provid groceri store on-line
pharmaci pharmaceut vendor chang competit landscap
impact rx volum neg impact compani sale earn
macroeconom regulatori climat uncertainti continu econom slowdown
 would bode poorli sinc above-averag unemploy rate drive lower level
consum spend would decreas prescript drug util regulatori environ
also fair amount uncertainti time impact variou healthcar reform
provis could materi impact wba oper nation emphasi reduc healthcar
cost could also spawn reimburs pressur new way contain healthcar cost
devis implement
intern exposur execut risk walgreen merger allianc boot increas
exposur intern market increas currenc exposur regulatori risk
wba partnership uniqu approach contract distribut
compani fail execut vision accret could expect
season time cost adjust swing result front-end sale
prescript sale compon season sale also lumpi depend
holiday line calendar sever cold cough flu season
magnitud compani lifo provis also fluctuat given quarter depend
inventori level sale inflat also swing result contribut earn
miss beat
amazon entri amazon may seek disrupt pharmaci market enter
retail market buy build contract pbm news topic pose
headlin risk share amazon could formid competitor mail cash pay
incom statement model fiscal year end august mm
sale
revenu
revenu
gross profit sg spread bp
equiti earn ab
share allianc boot associ
sale acquisit adjust
revenu
revenu
net earn attr nci
revenu
total non-gaap adjust tax
revenu
revenu
equiti earn allianc boot
sale acquisit adjust
compani report svb leerink llc estim
compani report svb leerink llc estim
incom statement model fiscal year end august mm
revenu
revenu
revenu
revenu
adjust equiti earn
elimin unalloc
sale
compani report svb leerink llc estim
incom statement model fiscal year end august mm
sale
equiti earn allianc boot
share allianc boot associ
previous held equiti interest
tax earn equiti method invest
net incom attrib non-control interest
net incom attrib walgreen
gain previous held equiti interest
increas decreas fair market valu warrant
partial releas capit loss valuat allow
loss sale busi
gain previous held equiti interest
increas decreas fair market valu warrant
partial releas capit loss valuat allow
compani report svb leerink llc estim
